What Is Janssen Doing To Increase Patient Diversity In Trials?

Patient diversity remains a problem in clinical trials. Although FDA-approved medicines serve a diverse population of Americans, participation in clinical trials remains predominantly white and male.

In this webinar segment, Cassandra Smith, director of diversity & inclusion in clinical trials for Janssen, discusses what Janssen is doing to increase recruitment of minority patients. The company started with a strategy to oversee the diversity effort. That strategy includes taking a close look at trial protocols, barriers to participation, and a careful site selection process. The strategy also involves sharing information about clinical research via educational outreach. Smith also discusses the factors that made the company’s LOTUS trial successful in recruiting women of color.